Izonsteride

Izonsteride (developmental code name LY-320,236) is a selective inhibitor of the 5α-reductase, with dual effects on both the type I and type II isoforms of the enzyme.[1] It was under development by Eli Lilly and Company and Fujisawa for the treatment of benign prostatic hyperplasia but was never marketed.[2][3] Izonsteride may also be useful in the treatment of androgenic alopecia.[1]

Izonsteride
Clinical data
Other namesLY-320,236
Routes of
administration		By mouth
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H26N2OS2
Molar mass422.61 g·mol−1
3D model (JSmol)

Chemistry

Synthesis

The scheme used to produce a somewhat more complex 5-a-reductase inhibitor relies on a chiral auxiliary to yield the final product as a single enantiomer. The first step starts with the reaction of bromotetralone with R-α-phenethylamine to afford the enamine. Reaction with methyl iodide adds the methyl group at what will be a steroid-like AB ring junction.

Preparation of Izonsteride

This product is then treated with acryloyl chloride. The initial step in this case probably involves the acylation of nitrogen on the enamine; conjugate addition then completes the formation of the lactam ring. Treatment of that product with triethyl silane then reduces the ring unsaturation and cleaves the benzylic nitrogen bond on the auxiliary to yield as the optically pure trans isomer. Displacement of bromine with the mercapto benzthiazole completes the synthesis of izonsteride.[4]

gollark: Welcome™!
gollark: You need to go in <#733816666089062511> or <#764137929638412328>.
gollark: They're quarantined.
gollark: The average server has about 10. We have 119. Thus we are 11.9 times better than average.
gollark: Well, anyway, we've got 116 bots!

See also

References
  1. Chang, Chawnshang (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4.
  2. "Present and future pharmacotherapy for benign prostatic hyperplasia".
  3. "Izonsteride - AdisInsight".
  4. Audia, J. R.; McQuaid, L. A.; Neubauer, B. L.; Rocco, V. P.; 1997, U.S. Patent 5,662,962.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.